Bicycle Therapeutics plc
BCYC
FAIR PRICE VALUATION
Updated daily
Model: DCF 50% · Relative 30% · Consensus 20%
MARKET PRICE
$4.34
FAIR PRICE
$6.43
MARGIN
$2.09
P/E Ratio
N/A
Div. Yield
N/A
ROE
-33.2%
Market Cap
$301M
Small-cap
COMING SOON
Get notified when BCYC's fair price changes
Fair Price Index app is launching soon with push notifications when valuations shift for stocks you follow.
iOS and Android · Free tier available
KEY FACTS
CEO
Kevin Lee
COUNTRY
GB
HEADQUARTERS
Cambridge
SECTOR
Healthcare
EXCHANGE
NASDAQ
METHODOLOGY
How we calculate BCYC's fair price
Bicycle Therapeutics plc's fair price of $6.43 is derived from a blended model that combines DCF analysis (50%), relative valuation against Healthcare peers (30%), and analyst consensus (20%). At the current market price of $4.34, BCYC trades 48.2% below its calculated fair value.
DCF MODEL · 50%
Discounted cash flow analysis based on projected free cash flows, discounted at a rate reflecting BCYC's risk profile.
RELATIVE · 30%
Comparing BCYC's valuation multiples against Healthcare peers.
ANALYST · 20%
Aggregated analyst price targets for BCYC, weighted by recency and analyst accuracy.
POWERED BY BULIOS
Get full analysis, financials, and AI insights for BCYC.
Explore on BuliosFAQ
What is the fair price of BCYC?+
Based on our blended model combining DCF analysis (50%), relative valuation against Healthcare peers (30%), and analyst consensus (20%), the fair price for Bicycle Therapeutics plc is $6.43. At the current market price of $4.34, BCYC trades 48.2% below its calculated fair value.
Is BCYC overvalued or undervalued?+
Bicycle Therapeutics plc is currently undervalued based on our valuation model. The stock trades at $4.34, which is 48.2% below the fair price of $6.43.
How often is BCYC's fair price updated?+
We update fair price calculations for BCYC daily after market close. The current fair price of $6.43 incorporates the latest market data and sector multiples.
What factors affect BCYC's fair price calculation?+
BCYC's fair price of $6.43 is derived from DCF analysis (50% weight), relative valuation against Healthcare peers (30% weight), and analyst consensus (20% weight)., ROE of -33.2%.
Is BCYC a good buy right now?+
At $4.34, BCYC trades 48.2% below our fair value estimate of $6.43. The stock is currently undervalued. ROE stands at -33.2% (average). Fair Price Index provides valuation data — always do your own research before investing.
Does BCYC pay dividends?+
BCYC does not currently pay a dividend.